Sajee Noitang

Sajee Noitang

Auto-generated profile, based on publicly available information

Sajee Noitang

Affiliation Research Unit in Bioconversion/Bioseparation for Value-Added Chemical Production, Institute of Biotechnology and Genetic Engineering, Chulalongkorn University, Pathumwan, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TKThanakrit Kaewsahnguan
Thanakrit Kaewsahnguan
SNSajee Noitang
Sajee Noitang
PSPapassara Sangtanoo
Papassara Sangtanoo
PSPiroonporn Srimongkol
Piroonporn Srimongkol
TSTanatorn Saisavoey
Tanatorn Saisavoey
Aphichart KarnchanatatAphichart Karnchanatat
Aphichart Karnchanatat
When fish are processed, fish bone becomes a key component of the waste, but to date very few researchers have sought to use fish bone to prepare protein hydrolysates as a means of adding value to the final product. This study, therefore, examines the potential of salmon bone, through an analysis of the benefits of its constituent components, namely fat, moisture, protein, and ash. In particular, the study seeks to optimize the process of enzymatic hydrolysis of salmon bone with trypsin in order to produce angiotensin-I converting enzyme (ACE) inhibitory peptides making use of response surface methodology in combination with central composite design (CCD). Optimum hydrolysis conditions concerning DH (degree of hydrolysis) and ACE-inhibitory activity were initially determined using the response surface model. Having thus determined which of the salmon bone protein hydrolysates (SBPH) offered the greatest level of ACE-inhibitory activity, these SBPH were duly selected to undergo ultrafiltration for further fractionation. It was found that the greatest ACE-inhibitory activity was achieved by the SBPH fraction which had a molecular weight lower than 0.65 kDa. This fraction underwent further purification using RP-HPLC, revealing that the F7 fraction offered the best ACE-inhibitory activity. For ACE inhibition, the ideal peptide in the context of the F7 fraction comprised eight amino acids: Phe-Cys-Leu-Tyr-Glu-Leu-Ala-Arg (FCLYELAR), while analysis of the Lineweaver-Burk plot revealed that the FCLYELAR peptide can serve as an uncompetitive ACE inhibitor. An examination of the molecular docking process showed that the FCLYELAR peptide was primarily able to provide ACE-inhibitory qualities as a consequence of the hydrogen bond interactions taking place between ACE and the peptide. Furthermore, upon isolation form the SBPH, the ACE-inhibitory peptide demonstrated ACE-inhibitory capabilities in vitro, underlining its potential for applications in the food and pharmaceutical sectors.

1 September 2019 in Industrial Crops and Products
Verified
Journal Article
Closed access
WSwinatta sakdasri
winatta sakdasri
SNSomkiat Ngamprasertsith
Somkiat Ngamprasertsith
SSSarintip Sooksai
Sarintip Sooksai
SNSajee Noitang
Sajee Noitang
WSWeradaj Sukaead
Weradaj Sukaead
Ruengwit SawangkeawRuengwit Sawangkeaw
Ruengwit Sawangkeaw

1 January 2020 in International Journal of Pharma Medicine and Biological Sciences
Verified
Journal Article
Open access
PBPatamalai Boonserm
Patamalai Boonserm
SPSongchan Puthong
Songchan Puthong
SNSajee Noitang
Sajee Noitang
TWThanaporn Wichai
Thanaporn Wichai
PKPongsak Khunrae
Pongsak Khunrae
SSSarintip Sooksai
Sarintip Sooksai